Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities.

Majid Mufaqam Syed-Abdul Elizabeth J ParksAyman H GaballahKimberlee BinghamGhassan M HammoudGeorge KembleDouglas BuckleyWilliam McCullochCamila Manrique-Acevedo

Published in: Hepatology (Baltimore, Md.) (2020)

These data support the therapeutic potential of a fatty acid synthase inhibitor, TVB-2640 in particular, in patients with NAFLD and nonalcoholic steatohepatitis.

Keyphrases

fatty acid
big data

machine learning
skeletal muscle

insulin resistance

artificial intelligence